SANTA BARBARA, Calif.--(BUSINESS WIRE)--Naryx Pharma, Inc., a leader in the development of new therapies for patients with chronic sinusitis, has completed enrollment of a 180 subject, randomized, double-blind, placebo-controlled Phase 2b trial of SybryxTM (tobramycin solution for nasal inhalation) for the treatment of chronic sinusitis in patients who have undergone previous sinus surgical procedures. The results of the trial will be announced after unblinding the data in the first quarter of 2008.
